🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to the The Royal Society of Medicine Radiology section for the invitation to speak this morning on the Urologists perspective of PSMA PET/CT for high-risk prostate cancer management with Prof. Tara Barwick #IP13AVIDITY I Imperial Prostate I Surgery and Cancer

It’s a big first day at #EAU25 for our clinical trials and PhD fellows! 🚀 Come along at 15:15 to ‘On the horizon: Ongoing trials in urology’ in Green Area, Retiro Nikhil Mayor presenting #IP7PACIFIC Alexander Light presenting #IP8FLUORESCE Archana Gopalakrishnan presenting #IP9ATLAS

Next is Archana Gopalakrishnan discussing the #IP9ATLAS trial For active surveillance, is regular MRI superior to standard care for detecting progression? Recruitment is open and the trial will randomise 1263 patients in 30 centres. Watch this space! #EAU25 🇪🇸

Nice presentation here at #EAU25 from my PhD student Archana Gopalakrishnan #IP9-ATLAS answering the question on MRI intensified active surveillance follow up vs standard of care - recruiting well in the UK

📣 Join Clinical Lecturer Mr Martin Connor as he presents the first Imperial Prostate randomised controlled trial - #IP2ATLANTA internal pilot results are out! Live on Monday 12:00 ⏱️ #EAU25 🇪🇸 #CytoreductiveSurgery #SABR #Ablation Martin J. Connor Hashim U. Ahmed Wellcome

It’s a big last day at #EAU25 for our team! 🇪🇸 Martin J. Connor - 2x #IP2ATLANTA pilot study results (12:00) Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05) Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)

#IP2-ATLANTA RCT pilot result #EAU25 🇪🇸 🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce 🚦Early signal in prostate cancer mortality for cytoreductive arms 📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027! Martin J. Connor

Fantastic by Martin J. Connor ! Look forward to read out in 2 years.

📢 Join us at Imperial Prostate We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04) 🔗 imperial.ac.uk/jobs/search-jo… Hashim U. Ahmed Martin J. Connor Taimur Shah

Ready to join Imperial Prostate? We are hunting for the next PhD Clinical Research Fellow for our 13th trial #AVIDITY. PSMA PET/CT only directed treatment in high-risk PCa (closing 15/04). APPLY 🔗: imperial.ac.uk/jobs/search-jo… Imperial Prostate I Hashim U. Ahmed I Imperial College London

Grateful to receive this award on behalf of the #IP2ATLANTA randomised controlled trial investigators 🏆 And the first 81 / 433 patients in 11 UK NHS hospital who accepted new combinations of cytoreductive treatments for their metastatic prostate cancer dhafer ben khalifa trust

📰Caval thrombectomy a urological leap into the unknown – a call for action? Paper in BJU International today - do join our recruiting multicentre #IR1CAVALThromb TheUrologyFoundation funded study improving outcomes from UK caval thrombectomy surgery! Archie Hughes-Hallett I bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

Another big day for Team IP with 3️⃣ presentations! 1️⃣ Hashim U. Ahmed (for Martin J. Connor): results of the #IP2ATLANTA RCT pilot (PD13: 10:50) 2️⃣ Chase Ng: 5y follow-up of ASAP & HGPIN in #RAPID (GG posters) 3️⃣ Archana Gopalakrishnan: update on #IB1LaserCOMPLETE (IP11; 09:30)

Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT. Presented here by Archana Gopalakrishnan Recruitment is under way - watch this space for results soon! #AUA25

Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by Hashim U. Ahmed #AUA25 Take home - these treatments are safe and justified Recruitment for the main trial has completed - PFS endpoint to be reported 2027

Brilliant 🤩 work from Archana Gopalakrishnan at #AUA25. IB1 LaserCOMPLETE TheUrologyFoundation funded trial is over 50% recruited. We look forward to sharing the results with everyone later this academic year!

Michael Hofman Boris Hadaschik Matthias Eiber Andrea Farolfi Thomas Hope Jeremie Calais Andrei Gafita Ken Herrmann Significant results on the prognostic value of NGI presence, distribution & volume of metastatic disease in mHSPC and mCRPC. Next step, to show in prospective RCTs that Rx changes improve outcomes #AVIDITY Imperial Prostate ESUR Junior Network

#IP2ATLANTA pilot published European Urology 🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce 🚦Early signal in prostate cancer mortality for cytoreductive arms 📈 Surgery, radiotherapy, ablation + SABR safe -> n=433 PFS exp.2027! euoncology.europeanurology.com/article/S2588-…

.European Urology Oncology Phase 2 RCT (IP2-ATLANTA, n=81) Cytoreductive surgery/radiotherapy/ablation for de novo mHSPC showed feasibility (75% recruitment) and safety (11% pathologic CR, 7-18% grade ≥3 AEs). PMID:40517058 pubmed.ncbi.nlm.nih.gov/40517058/

Congratulations to the #IP2ATLANTA trials team on their presentation being selected for best of #BAUS25 Hashim U. Ahmed Martin J. Connor